Brisk M&A Activity Reviving Indian CRO Scene
This article was originally published in PharmAsia News
Clinical trial approvals in India have declined sharply in recent months but that has not held back companies active in the sector – both local and global – from making acquisitions. The trend may continue as a few more deals are said to be on the anvil.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.